^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Excerpt:
We next evaluated the activity of ponatinib in ER-negative breast cancer cell lines, SUM 52PE and MFM-223, that overexpress FGFR2 due to genomic amplification. Ponatinib inhibited growth of SUM 52PE and MFM-223 cells with GI50 values of 14 and 69 nmol/L, respectively (Fig. 5B).
DOI:
10.1158/1535-7163.MCT-11-0450